Nakaseomyces glabrata endocarditis: A therapeutic dilemma

Kin Ki Jim; Joelle J N Daems; S Matthijs Boekholdt; Karin van Dijk

doi:10.1016/j.mmcr.2023.04.002

Nakaseomyces glabrata endocarditis: A therapeutic dilemma

Med Mycol Case Rep. 2023 Apr 28:40:54-57. doi: 10.1016/j.mmcr.2023.04.002. eCollection 2023 Jun.

Authors

Kin Ki Jim^{1

2}, Joelle J N Daems³, S Matthijs Boekholdt³, Karin van Dijk^{1

2}

Affiliations

¹ Amsterdam UMC Location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Meibergdreef 9, Amsterdam, 1105 AZ, the Netherlands.
² Amsterdam Institute for Infection and Immunity, De Boelelaan 1085, Amsterdam, 1081 HV, the Netherlands.
³ Amsterdam UMC Location University of Amsterdam, Department of Cardiology, Meibergdreef 9, Amsterdam, 1105 AZ, the Netherlands.

Abstract

Candida infective endocarditis is a rare but serious entity that often requires aggressive treatment. However, treatment can be challenging in patients infected with drug-resistant fungi and/or with substantial comorbidity. Moreover, recommendations in treatment guidelines for these patients are based on limited clinical data due to their rarity. Here we report a case of Nakaseomyces glabrata (Candida glabrata) prosthetic valve endocarditis in a patient with congenital heart disease. This case illustrates a therapeutic dilemma for Nakaseomyces glabrata prosthetic valve endocarditis and the need for novel antifungal drugs and further clinical studies.

Keywords: Anti-fungal therapy; Candida glabrata; Endocarditis; Invasive candidiasis; Nakaseomyces glabrata.

Publication types

Case Reports